NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCTs031180403

Registered date:20/03/2019

PIT-2

Basic Information

Recruitment status Not Recruiting
Health condition(s) or Problem(s) studiedPrimary lung cancer
Date of first enrollment18/04/2014
Target sample size45
Countries of recruitment
Study typeInterventional
Intervention(s)The surgical resection is performed after 3 cycles of induction concurrent chemoradiotherapy with CDDP, TS-1 and RT45Gy (1.8Gy/fra/day, 25fractions).

Outcome(s)

Primary Outcome2-year progression-free survival
Secondary Outcome- 5-year progression-free survival - 2-year and 5-year overall survival - Completion rate of the protocol treatment - Complete resection rate - Radiological response rate - Down staging rate - Safety - Pathological response (Ef) - Tumor markers (CEA/CYFRA) - SUVmax on FDG-PET scan

Key inclusion & exclusion criteria

Age minimum>= 20age old
Age maximum<= 75age old
GenderBoth
Include criteria(1) Histologically or cytologically proven squamous cel carcinoma of the lung, diagnosed using specimen material (2) Stage IIIA- pathologically proven N2 disease (3) Without previously treatment for lung cancer (4) 20 years or more , 75 years or less (5) ECOG PS 0-1 (6) Expected FEV 1.0 > 800ml after lung resection , SpO2 (Room air) >95% (7) Adequate organ function (8) Written informed consent
Exclude criteria(1) Uncontrollable systemic disease (hyper tension, diabetes mellitus etc.) (2) Under administration of flucytosine (3) History of active infection (4) Hepatitis Bs antigen positive (5) History of severe heart disease (6) Traumatic fracture of un recovery (7) Severe diarrhea (8) Severe drug allergy (9) Investigational new drug or the unapproved drug is administered (10) Interstitial pneumonia or pulmonary fibrosis detectable on chest CT (11) History of active double cancer (12) History of pregnancy or lactation (13) Any other medical condition that makes the patient unsuitable for inclusion in the study according to the opinion of the investigator

Related Information

Contact

Public contact
Name Kazuya Takamochi
Address 3-1-3, Hongo, Bunkyo-ku, Tokyo Tokyo Japan 113-8431
Telephone +81-3-3813-3111
E-mail ktakamo@juntendo.ac.jp
Affiliation Juntendo University Hospital
Scientific contact
Name Kenji Suzuki
Address 3-1-3, Hongo, Bunkyo-ku, Tokyo Tokyo Japan 113-8431
Telephone +81-3-3813-3111
E-mail kjsuzuki@juntendo.ac.jp
Affiliation Juntendo University Hospital